Abstract:The adoptive transfer of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 has shown remarkable activity for patients with B cell malignancies. Using a second- generation CAR signaling through 4-1BB/CD3ζ, (CTL019), over 90% of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) will achieve complete remission (Maude, S.L. et. al. New England Journal of Medicine, 2014). Similar therapy can induce long-term remissions for R/R chronic lymphocytic leukemia (CLL), but only in a subset of patients (Porter, D.L. et. al. Science Transl. Medicine, 2015). The ability to identify individuals most likely to respond will have a dramatic impact on patient selection and provide critical information that may allow immune modification to enhance responses using this approach. We here present updated analyses and functional validation of our previously reported biomarker profiles of CTL019 cells in CLL (Fraietta, J.A. et. al., Blood, 2016). Retrospective samples of clinically manufactured CAR T cells from forty-one patients with advanced, heavily pre-treated and high-risk CLL were evaluated for functional determinants of potency. Transcriptomic analysis of CTL019 cells from subjects who had complete responses (CR) to this therapy revealed enrichment in early memory T cells and IL-6/STAT3 gene signatures, while T cells from non-responding (NR) patients were enriched in genes belonging to known pathways of terminal differentiation, exhaustion, apoptosis and glycolysis. Accordingly, CAR-stimulated T cells from NR relative to CR patents demonstrated an increased uptake of a glucose analog; inhibition of glycolysis using 2-deoxy-D-glucose resulted in the generation of early memory CAR T cells in culture. Furthermore, CTL019 cells that were highly functional in CLL patients had increased levels of phosphorylated STAT3 (pSTAT3) upon activation compared to CAR T cells from NR patients with poor anti-tumor activity. These data were concordant with the highly significant direct correlation between serum IL-6 and the degree of CTL019 proliferative capacity in patients. Increasing pSTAT3 activity by addition of exogenous IL-6 to culture media elevated the absolute numbers of CAR T cells following repeated stimulation with CD19-expressing tumor targets, while pSTAT3 inhibition diminished CTL019 cell growth. Single-cell proteomic analysis of CAR-stimulated CTL019 cells from CLL patients revealed marked heterogeneity in cytokine secretions and enhanced polyfunctional strength in CAR T cells from responding over non-responding patients. There were multiple contributors to CTL019 cell polyfunctional strength, including granzyme B, MIP-1α, IFNg, TNFα, IL-5, IL-8, MIP-1β and perforin. We next performed deep immunophenotyping on the above pre-infusion CAR T cells and, through unbiased computational analysis of the flow cytometry data, defined a single subset (CD8+CD27-PD1-) that segregated CRs from NRs. Importantly, we noted a highly significant association between the likelihood of having a response to CTL019 therapy and the infusion of CTL019 products containing a high dose of CD8+PD1-CD27+ CAR T cells. To confirm that this cell population drives the response to CTL019 therapy, we depleted it from CR patient CTL019 cells and observed loss of tumor control and decreased survival in leukemia-bearing NOD scid gamma (NSG) mice compared to animals treated with subject-matched unmanipulated cellular products. These findings, coupled with our previous results, reveal a functionally relevant T lymphocyte population that can serve as a novel predictive biomarker and a framework for future mechanistic dissection to enhance the efficacy of CAR T cell therapies. Disclosures Fraietta: Novartis: Patents & Royalties: patents, Research Funding. Lacey: Novartis: Research Funding; Genentech: Honoraria. Orlando: Novartis: Employment. Pruteanu: Novartis Pharmaceuticals Corporation: Employment. OConnor: Novartis: Research Funding. Chen: Novartis: Research Funding. Davis: Novartis: Research Funding. Young: Novartis: Research Funding. Levine: Brammer Bio: Consultancy; Tmunity Therapeutics: Equity Ownership, Research Funding; GE Healthcare: Consultancy; Novartis Pharmaceuticals Corporation: Patents & Royalties, Research Funding. Siegel: Novartis: Research Funding. Zhou: IsoPlexis: Employment, Equity Ownership. Paczkowski: IsoPlexis: Employment, Equity Ownership. Mackay: IsoPlexis: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Speakers Bureau. Brogdon: Novartis: Employment. Bitter: Novartis: Employment. Porter: Incyte: Honoraria; Novartis: Honoraria, Patents & Royalties, Research Funding; Servier: Honoraria, Other: Travel reimbursement; Genentech/Roche: Employment, Other: Family member employment, stock ownship - family member; Immunovative Therapies: Other: Member DSMB. June: Tmunity Therapeutics: Equity Ownership, Research Funding; WIRB/Copernicus Group: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celldex: Honoraria, Membership on an entity's Board of Directors or advisory committees; Immune Design: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Novartis: Patents & Royalties, Research Funding. Melenhorst: Novartis: Research Funding.

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia

Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

CD19-CAR Cytokine Induced Killer Cells Armored with IL-18 Control Tumor Burden, Prolong Mouse Survival and Result in In Vivo Persistence of CAR-CIK Cells in a Model of B-Cell Acute Lymphoblastic Leukemia

Novel Immunotherapy Targets for Relapsed/Refractory B-ALL: A Literature Review

In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence

Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR